RxDoctor Payments Data

Schuyler Williams

Internal Medicine · New Orleans, LANPI 1629500871

Payments from drug & device makers

$1,275in general payments, 2019–2025

Across 64 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$302
  • GSK$260
  • Lilly USA, LLC$191
  • Medtronic$97
  • AstraZeneca$92
  • Gilead$50
  • plus $282 from 12 others

What the payments were for

  • Food & beverage$1,275100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,275 in reported general payments places this provider in the 65th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$34,559
Medicare patients
119
Services billed
490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide133$183,237
MounjaroTirzepatide75$122,164
JanuviaSitagliptin Phosphate70$100,576
EliquisApixaban98$76,159
TrulicityDulaglutide55$75,500
JardianceEmpagliflozin46$66,904
LinzessLinaclotide29$31,605
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$20,912
TradjentaLinagliptin18$15,129
Breo ElliptaFluticasone/Vilanterol24$12,768
Soliqua 100-33Insulin Glargine/Lixisenatide12$11,596
Spiriva HandihalerTiotropium Bromide17$10,895
FarxigaDapagliflozin Propanediol15$10,062
SymbicortBudesonide/Formoterol Fumarate34$9,565
Lantus SolostarInsulin Glargine,hum.Rec.Anlog90$8,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$191$197,663130 claims
Novo NordiskOzempic$16$183,237133 claims
PfizerEliquis$302$76,15998 claims
AbbVieLinzess, Synthroid$43$34,93658 claims
GSKTrelegy Ellipta, Breo Ellipta$260$33,68058 claims
AstraZenecaFarxiga, Symbicort$92$19,62649 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$20$11,59612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →